Cargando…
Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study
BACKGROUND: Fibrosing interstitial lung disease (F-ILD) is a major public health concern due to its poor prognosis. Recent clinical evidence shows that antifibrotic approaches such as pirfenidone and nintedanib provide better clinical outcome prediction in idiopathic pulmonary fibrosis (IPF) as well...
Autores principales: | Joung, Kyung-In, Park, Hyemin, Park, Sunyoung, Shin, Ju-Young, Kim, Yong Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035232/ https://www.ncbi.nlm.nih.gov/pubmed/36949407 http://dx.doi.org/10.1186/s12890-023-02373-z |
Ejemplares similares
-
Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021) -
Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021) -
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023) -
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021) -
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)